BELLEROPHON

comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN

 Coordinatore THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Dr.
Nome: Stephen
Cognome: Conway
Email: send email
Telefono: +44 1865 289800
Fax: +44 1865 289801

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 7˙105˙812 €
 EC contributo 5˙498˙829 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-2
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-09-01   -   2016-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Dr.
Nome: Stephen
Cognome: Conway
Email: send email
Telefono: +44 1865 289800
Fax: +44 1865 289801

UK (OXFORD) coordinator 2˙022˙378.00
2    IMAXIO SA

 Organization address address: RUE SAINT ROCH 5/7
city: PARIS
postcode: 75001

contact info
Titolo: Mr.
Nome: Alexandre
Cognome: Le Vert
Email: send email
Telefono: +33 6 79 82 92 70
Fax: +33 4 74 26 15 78

FR (PARIS) participant 2˙505˙885.00
3    EUROPEAN VACCINE INITIATIVE - EEIG

 Organization address address: IM NEUERHEIMER FELD 307
city: Heidelberg
postcode: 69120

contact info
Titolo: Mr.
Nome: Sten
Cognome: Larsen
Email: send email
Telefono: 4530423159

DE (Heidelberg) participant 518˙566.00
4    PRECLIN BIOSYSTEMS AG

 Organization address address: ROUTE DE LA CORNICHE 4
city: EPALINGES
postcode: 1066

contact info
Titolo: Dr.
Nome: Bettina
Cognome: Ernst
Email: send email
Telefono: +41 795612794
Fax: 41216519009

CH (EPALINGES) participant 452˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

manufacture    initial    antibiotic    viral    antigens    vaccine    antigen    pathogens    aureus    reduce    clinical    components    bacterial    series    proprietary    vectors    protective    mrsa    innovative   

 Obiettivo del progetto (Objective)

'Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals. Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA or EMEA, prevention also relies heavily on antimicrobials to which antibiotic resistance is developing.

To reduce S. aureus disease burden, and antibiotic use associated with it, BELLEROPHON will design, manufacture, and assess in a Phase I clinical study a novel S. aureus vaccine candidate targeting both the cellular and humoral responses. It is designed to be protective against both MRSA and more sensitive S. aureus strains.

The project will rely on 4 key components: i) a recently discovered and highly conserved T-cell inducing antigen individually capable of eliciting substantial protection in mouse models; (ii) a secreted toxin antigen, antibodies against which reduce mortality (Hla); (iii) an innovative, proprietary and potent pro-immunogenic series of tags (IMX313 series) which can be fused to the antigens; (iv) the use of viral vectors, including an innovative and proprietary adenoviral vector (ChAdOx1) and/or new ways to use viral vectors to generate protective immunity (MVA mixed with proteins).

We will i) identify the most protective method of combining these components in a manufacturable and clinically deployable manner; ii) manufacture and perform initial human studies of the vaccine; iii) identify additional antigens which might further increase the efficacy of the initial product.

Our approach will contribute clinical safety and immunogenicity data for a novel vaccine strategy targeting one of the key bacterial pathogens in man. It will pave the way for rapid progression to phase II studies, and thence to larger phase II/III studies aiming to reduce infection.'

Altri progetti dello stesso programma (FP7-HEALTH)

IPROVE (2013)

Innovation Partnership for a Roadmap on Vaccines in Europe

Read More  

GAPP (2013)

GAbapentin in Paediatric Pain

Read More  

CCH FEVER (2010)

"Crimean Congo Hemorrhagic Fever; Modern Approaches to Diagnostics, Surveillance, Prevention, Therapy and Preparedness."

Read More